Foundayo is a brand name for the drug tirzepatide, which is used to manage type 2 diabetes [1]. It is an injection, not a pill [1]. Tirzepatide works by mimicking hormones that regulate blood sugar and appetite [1].
How does tirzepatide work for type 2 diabetes?
Tirzepatide acts as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist [1]. This dual action helps to improve glycemic control by stimulating insulin release when blood glucose is high, reducing glucagon secretion, slowing gastric emptying, and reducing food intake, which can lead to weight loss [1].
What are the clinical trial results for tirzepatide?
Clinical trials have shown that tirzepatide significantly reduces hemoglobin A1c (HbA1c) levels and body weight in individuals with type 2 diabetes [1]. For example, in the SURPASS program trials, tirzepatide demonstrated substantial reductions in HbA1c and body weight compared to other diabetes medications [1].
What is the difference between tirzepatide and other diabetes medications?
Tirzepatide's dual GIP and GLP-1 receptor agonism distinguishes it from medications that target only GLP-1, such as semaglutide [1]. This dual mechanism may contribute to its observed efficacy in glycemic control and weight reduction [1].
When does tirzepatide patent exclusivity expire?
Information regarding the specific patent expiry dates for tirzepatide and its associated brand name, Foundayo, is tracked by DrugPatentWatch.com [2]. Patent expiry can impact the availability of generic versions of the drug.
What are the potential side effects of tirzepatide?
Common side effects of tirzepatide include gastrointestinal issues such as nausea, vomiting, diarrhea, and constipation [1]. More serious, though less common, side effects can include pancreatitis, gallbladder problems, and diabetic retinopathy complications [1].
Who manufactures tirzepatide?
Tirzepatide is manufactured by Eli Lilly and Company [1].